CANbridge Pharmaceuticals Inc. (HKG:1228)
Hong Kong · Delayed Price · Currency is HKD 2.005
+0.095 (4.97%)
Sep 18, 2026, 4:08 PM HKT
CANbridge Pharmaceuticals Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 55.68 | 49.98 | 85.1 | 102.87 | 78.97 | 31.16 | |
Revenue Growth | -11.00% | -41.27% | -17.27% | 30.26% | 153.43% | 158.98% |
Cost of Revenue | 15.11 | 12.66 | 30.8 | 38.71 | 30.08 | 12.39 |
Gross Profit | 40.56 | 37.33 | 54.3 | 64.16 | 48.89 | 18.78 |
Selling, General & Admin | 99.14 | 84.2 | 143.06 | 173.5 | 195.69 | 246.27 |
Research & Development | 39.57 | 45.05 | 251.76 | 257.21 | 311.17 | 427.66 |
Operating Expenses | 138.7 | 129.25 | 394.82 | 430.71 | 506.86 | 673.92 |
Operating Income | -98.14 | -91.93 | -340.52 | -366.55 | -457.97 | -655.15 |
Interest Expense | -0.71 | -2.23 | -8.58 | -8.95 | -6.86 | -3.08 |
Interest & Investment Income | 0.74 | 0.37 | 0.51 | 10.98 | 3.89 | 2.61 |
Currency Exchange Gain (Loss) | 8.23 | 8.23 | -7.04 | - | - | 0.63 |
Other Non Operating Income (Expenses) | 8.93 | -1.03 | 0.19 | -14.56 | -22.97 | 30.69 |
EBT Excluding Unusual Items | -80.94 | -86.58 | -355.44 | -379.08 | -483.91 | -624.3 |
Gain (Loss) on Sale of Assets | 0.16 | 1.09 | 2.2 | - | 0.44 | 9.73 |
Asset Writedown | -0.73 | -0.73 | -89.41 | - | - | - |
Other Unusual Items | -0 | 101.04 | 0.03 | 0.24 | - | -462.44 |
Pretax Income | -81.51 | 14.82 | -442.62 | -378.84 | -483.48 | -1,077 |
Net Income | -81.51 | 14.82 | -442.62 | -378.84 | -483.48 | -1,077 |
Net Income to Common | -81.51 | 14.82 | -442.62 | -378.84 | -483.48 | -1,077 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 523 | 454 | 425 | 424 | 424 | 94 |
Shares Outstanding (Diluted) | 523 | 457 | 425 | 424 | 424 | 94 |
Shares Change | 23.16% | 7.60% | 0.11% | 0.04% | 350.13% | 37.39% |
EPS (Basic) | -0.16 | 0.03 | -1.04 | -0.89 | -1.14 | -11.43 |
EPS (Diluted) | -0.16 | 0.03 | -1.04 | -0.89 | -1.14 | -11.43 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | - | -38.22 | -122.5 | -283.38 | -296.18 | -592.16 |
Free Cash Flow Per Share | - | -0.08 | -0.29 | -0.67 | -0.70 | -6.28 |
Gross Margin | 72.86% | 74.67% | 63.81% | 62.37% | 61.91% | 60.26% |
Operating Margin | -176.27% | -183.92% | -400.12% | -356.32% | -579.91% | -2102.46% |
Profit Margin | -146.41% | 29.65% | -520.10% | -368.26% | -612.21% | -3456.26% |
Free Cash Flow Margin | - | -76.46% | -143.94% | -275.47% | -375.04% | -1900.31% |
EBITDA | -87.25 | -81 | -326.8 | -354.72 | -448.84 | -646.11 |
EBITDA Margin | -156.72% | -162.05% | - | - | - | - |
D&A For EBITDA | 10.89 | 10.93 | 13.72 | 11.82 | 9.13 | 9.04 |
EBIT | -98.14 | -91.93 | -340.52 | -366.55 | -457.97 | -655.15 |
EBIT Margin | -176.27% | -183.92% | - | - | - | - |